ATI-2138 and ritlecitinib were assessed using a reversal model of murine alopecia universalis, the most severe AA phenotype.
Aclaris Therapeutics reported early study results showing its ATI-2138 drug drove rapid and lasting hair regrowth, ...
Nektar Therapeutics is expected to announce topline data from the REZOLVE-AA trial in December 2025. The Food and Drug Administration (FDA) has granted Fast Track designation to rezpegaldesleukin for ...
Severe alopecia areata may be driven by broader immune activation than previously recognized, according to new research ...
Credit: SUN Pharma. Leqselvi is supplied as a tablet containing 8mg of deuruxolitinib. Prior to initiating treatment with Leqselvi, certain evaluations and immunizations are recommended. Leqselvi ™ ...
FILE PHOTO: The Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo (Reuters) -Eli Lilly announced on Friday ...
Nektar Therapeutics released data from a study of its rezpegaldesleukin drug, establishing proof-of-concept in patients with severe to very severe alopecia areata, a hair-loss condition. Mean percent ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Baricitinib maintained hair regrowth among adolescents ...
Alopecia areata causes hair loss on the scalp or other body parts such as the eyebrows. New treatments like Olumiant offer hope for some people. This FDA-approved medicine works in unique ways to help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results